Alzheimer’s Disease research is advancing with developments like Roche’s new biomarker blood test. Yet 98% of AD clinical ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Fosun Pharma is spending 1.4 billion Chinese yuan ($200 million) to take on a 53% stake in Green Valley Pharmaceuticals and ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two major trials last month that found an older drug similar to Ozempic had no effect in slowing ...

Eli Lilly received expanded approval from the U.S. Food and Drug Administration for Jaypirca, a treatment for adults with certain types leukemia and lymphoma. The approval expands Jaypirca to include ...